Zacks Investment Research downgraded Laboratory Corp. of America Holdings (NYSE:LH) to Hold in a statement released earlier today.
- Updated: October 7, 2016
Boasting a price of $137.14, Laboratory Corp. of America Holdings (NYSE:LH) traded 1.01% higher on the day. With the last stock price close up 6.31% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Laboratory Corp. of America Holdings has recorded a 50-day average of $136.75 and a two hundred day average of $130.62. Volume of trade was up over the average, with 931,437 shares of LH changing hands over the typical 675,791
Zacks Investment Research has downgraded Laboratory Corp. of America Holdings (NYSE:LH) to Hold in a statement released on 10/07/2016.
On Tuesday October 04, 2016, Zacks Investment Research released a statement for Laboratory Corp. of America Holdings (NYSE:LH) bumped up the target price from $0.00 to $153.00 that suggested an upside of 0.13%.
With a total market value of $0, Laboratory Corp. of America Holdings has price-earnings ratio of 23.06 with a one year low of $97.79 and a one year high of $141.32 .
A total of 17 equity analysts have released a ratings update on LH. Four equity analysts rating the company a strong buy, ten equity analysts rating the company a buy, six equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $140.94.
Brief Synopsis About Laboratory Corp. of America Holdings (NYSE:LH)
Laboratory Corporation of America Holdings is a healthcare diagnostics company. The Company, together with its subsidiaries, is engaged in providing clinical laboratory services and drug development support. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD). The Company's LCD segment is an independent clinical laboratory business that consists of a network of approximately 40 primary laboratories and approximately 1,700 patient service centers (PSCs) along with a network of branches and STAT laboratories, which offer a menu of routine and frequently ordered tests. LCD offers a menu of over 4,700 tests, such as blood chemistry analyses, urinalyses, blood cell counts and thyroid tests. Its CDD segment offers drug development services, and provides a range of drug development solutions across the world, primarily to companies in the pharmaceutical and biotechnology industries.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.